Horus Pharma announces strategic Agreement to commercialize Formycon’s Aflibercept Biosimilar
Expanding Horus Pharma’s Portfolio into Retina
Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of Formycon’s Eylea® biosimilar FYB203 (Aflibercept) under the brand name Baiama® in selected European countries.
A Strategic Step for Horus Pharma’s European Growth
- Press release_Strategic AgreementDownload